Feb 06, 09
|
| NEW STORY |
| 13:44 ET |
Diffusion Pharmaceuticals Announces Completion of a $2.9 Million Private Placement and Company Presentations at Upcoming Industry Conferences in Geneva, Switzerland and Naples, Florida
|
 |
Sep 03, 08
|
| 09:21 ET |
Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD)
|
|
| 09:02 ET |
Diffusion Pharmaceuticals Announces Initiation of a Phase I/II Clinical Trial in Patients with Peripheral Arterial Disease (PAD)
|
|
Jun 10, 08
|
| 14:30 ET |
Diffusion Pharmaceuticals Announces Addition of Mark T. Giles to its Board of Directors
|
|
Apr 08, 08
|
| 14:58 ET |
Diffusion Pharmaceuticals Announces Issuance of U.S. Patent No. 7351844, Titled 'Bipolar Trans Carotenoid Salts and Their Uses,' for Its Family of First-In-Class Molecules
|
|
Dec 21, 07
|
| 12:03 ET |
Co-Inventor of Amgen's Aranesp(R) Technology Directs Worldwide Patent Strategy for Diffusion Pharmaceuticals' First-in-Class Oxygen Enhancing Therapeutics
|
|
Sep 28, 07
|
| 11:04 ET |
Diffusion Pharmaceuticals Announces Results of Phase I Human Trial of Lead Drug Candidate, Trans Sodium Crocetinate (TSC) and Completion of a $4.5 Million Private Placement
|
|
Apr 26, 07
|
| 14:29 ET |
Diffusion Pharmaceuticals Announces Formation of Scientific Advisory Board Chaired by Company Co-founder, John L. Gainer, Ph.D.
|
|
Mar 16, 07
|
| 14:43 ET |
Diffusion Pharmaceuticals Initiates Human Trial of Lead Drug Candidate, Trans Sodium Crocetinate (TSC)
|
|
Feb 02, 07
|
| 11:22 ET |
Diffusion Pharmaceuticals Announces Additional Funding from the Office of Naval Research (ONR) Bringing the Company's Total Navy Funding to $2.6 Million
|
|
Nov 14, 06
|
| 14:07 ET |
Diffusion Pharmaceuticals Strengthens Management Team With Appointment of Matthew W. Hantzmon as Vice President, Business Development
|
|
Oct 17, 06
|
| 12:33 ET |
Diffusion Pharmaceuticals Completes FDA-Required Toxicology Studies in Support of Phase I Trials and Closes $1.5 Million Private Placement
|
|
Feb 21, 06
|
| 15:09 ET |
Diffusion Pharmaceuticals LLC Resumes Toxicology Studies with MPI Research; Company Advances Toward Filing Investigational New Drug Application
|
|
Mar 01, 05
|
| 12:06 ET |
Diffusion Pharmaceuticals LLC Announces Strategic Alliance to Develop New Cancer Therapies
|
|
Oct 29, 04
|
| 16:39 ET |
Diffusion Pharmaceuticals LLC Wins Business Plan Competition and Receives $10,000 Cash Prize in Virginia's Technology Capital Access Forum
|
|
Oct 25, 04
|
| 13:47 ET |
Diffusion Pharmaceuticals LLC Selected to Present at Virginia's Technology Capital Access Forum and Announces that Corporate Finance Veteran, Ben Shealy, Joins Its Management Team
|
|
Sep 08, 04
|
| 15:26 ET |
Diffusion Pharmaceuticals Announces $1 Million Grant and, Citing Growth, Two New Hires
|
|
Jul 28, 04
|
| 14:52 ET |
Diffusion Pharmaceuticals Raises $2.1 Million in Private Equity Round; Human Testing of its Lead Compound TSC Planned for 2005
|
|
Feb 17, 04
|
| 17:09 ET |
Diffusion Pharmaceuticals to Present at BIO CEO & Investor Conference February 2004
|
|
Feb 09, 04
|
| 12:05 ET |
Diffusion Pharmaceuticals Announces Navy Funding and Key Staff Appointments
|
|
Feb 04, 04
|
| 17:37 ET |
Diffusion Pharmaceuticals Appoints David Kalergis as CEO
|
|